Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 7/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 4/20 | 0.43 |
| ▸ | RARG | P13631 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9071061 | 0.94 | GCK (0.54) | GCKKCNH2GRM5RARGCYP3A4 | |
| SCHEMBL9070855 | 0.91 | MAPK1 (0.51) | GCKKCNH2CYP3A4MAPK1HTT | |
| SCHEMBL9071045 | 0.85 | CPT1A (0.43) | GRM5CYP3A4DRD3SLC6A3MAPK1 | |
| SCHEMBL2667799 | 0.85 | MAPK1 (0.55) | GCKKCNH2CYP3A4MAPK1HTT | |
| SCHEMBL9071064 | 0.84 | GCK (0.70) | GCKKCNH2RARG | |
| SCHEMBL2667538 | 0.83 | GCK (0.50) | GCKKCNH2GRM5RARGRAB9A | |
| SCHEMBL2667580 | 0.83 | GCK (0.50) | GCKKCNH2GRM5RARGRAB9A | |
| SCHEMBL2667825 | 0.83 | GRM5 (0.58) | GCKGRM5RARGCYP3A4DRD3 | |
| SCHEMBL2667802 | 0.83 | GCK (0.50) | GCKKCNH2GRM5RARGRAB9A | |
| SCHEMBL2667828 | 0.82 | GCK (0.48) | GCKKCNH2GRM5MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009083553-A1 | AZINE COMPOUNDS AS GLUCOKINASE ACTIVATORS | RHEOSCIENCE A/S (DK) | 2009-07-09 | — | — | WO | disclosed |